This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
by Zacks Equity Research
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
LGNDPositive Net Change FOLDNegative Net Change ANIPPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CMMBPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Snap (SNAP) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SNAPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Byline Bancorp (BY) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
First Community Bancshares (FCBC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FCBCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
NBIXNegative Net Change ANIPPositive Net Change XENENegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
RHHBYPositive Net Change BMYPositive Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
by Zacks Equity Research
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
LGNDPositive Net Change CPRXPositive Net Change ANIPPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Lilium N.V. (LILM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
LILMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
WhiteHorse Finance (WHF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
WHFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
LGNDPositive Net Change ANIPPositive Net Change ACADPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
LGNDPositive Net Change ANIPPositive Net Change ITCIPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
LGNDPositive Net Change PCRXNegative Net Change ANIPPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
by Zacks Equity Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ARGXPositive Net Change
biotechnology medical
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
SNYPositive Net Change BIIBPositive Net Change LGNDPositive Net Change DNLIPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
LGNDPositive Net Change ANIPPositive Net Change APLSNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
ANIPPositive Net Change ADVMPositive Net Change ARVNPositive Net Change ABSINegative Net Change
biotechnology biotechs pharmaceuticals
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
CPRXPositive Net Change ADVMPositive Net Change ARGXPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
CPRXPositive Net Change ANIPPositive Net Change ADVMPositive Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
BMRNPositive Net Change LGNDPositive Net Change BPMCNegative Net Change IMVTNegative Net Change KYMRNegative Net Change
biotechnology biotechs
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
REGNPositive Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
REGNPositive Net Change LGNDPositive Net Change ANIPPositive Net Change RAREPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
SNYPositive Net Change AMRNPositive Net Change ANIPPositive Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
by Zacks Equity Research
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
LGNDPositive Net Change ANIPPositive Net Change BPMCNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
by Zacks Equity Research
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
GSKPositive Net Change BMYPositive Net Change GILDPositive Net Change EDITPositive Net Change DCPHPositive Net Change
biotechnology